Several UK companies are vying to replace Palantir in the NHS, the Financial Times reported at 05:00 UTC on 16 November, after the government signalled it would put the Federated Data Platform contract up for tender on terms more favourable to British groups. According to the FT, the government is expected to rule out triggering a break clause that would allow the NHS to sever ties with Palantir by March, but will instead announce a new procurement process to allow a UK alternative to bid.
The contract’s award notice on Contracts Finder lists a value of £182,242,760 and says the value could increase to a forecasted amount of £330m, a figure it says is also not a committed amount. The notice value is about 55% of the £330m forecast, by our arithmetic.
Business Pill · Sovereign AI Explained
An evergreen Business Engineer explainer on sovereign AI, why states treat AI capability as strategic. It teaches the general idea only and does not discuss Palantir or the NHS.
The key insight: As we read it, the FT report describes a middle path: no break at the three-year point, but a new tender that UK groups are preparing to bid for, on a contract whose £330m forecast averages about £47 million a year over seven years, by our arithmetic. No government announcement of the process was in anything we read.
Who Is Lining Up
The FT reports that at least two rival groups are preparing bids. On Monday, a British-led consortium of more than 20 companies announced it would be bidding to take on management of the platform, according to the FT. The group, known as Drystone Health AI Collaboration, is led by Shane Tickell, head of health consultancy Temple Black.
“I do not believe [Palantir] provides good value for the NHS,” Tickell told the FT. The consortium includes Voror Health Technologies and Black Pear Software, two NHS contractors that had previously bid for the contract, plus the UK arm of VitalHub, listed on the Toronto Stock Exchange, and IMS Maxims, a subsidiary of TSX-listed Constellation Software, the FT reports.
London-based Quantexa is understood to be preparing a fresh bid after losing out three years ago, and is seen as the frontrunner if the government decides on a British firm, the FT reports. The FT says Quantexa has contracts with HMRC and banks including HSBC and Standard Chartered, and is said to be open to a model where different companies manage the platform for different parts of the NHS.
Oracle Health is also seen as a potential bidder after making the final stage of the 2023 process, according to the FT. Palantir may seek to retain the contract by arguing it should be considered a UK company, and ministers are working on a new definition of a “UK supplier” for procurement purposes, the FT reports. Palantir declined to comment, Quantexa declined to comment and Oracle Health did not respond, the FT says.

What the Contract Says
NHS England awarded the contract, Federated Data Platform and Associated Services, to Palantir Technologies UK on 22 November 2023 after a competitive dialogue, according to the award notice. NHS England’s contract explainer names Accenture, PwC, Carnall Farrar and NECS as consortium members and says the contract formally began in March 2024.
The notice says NHS England pays for data platform services as they are consumed, according to an agreed pricing schedule. Over the seven-year maximum term, the £330m forecast averages about £47 million a year, by our arithmetic.
NHS England says only a three-year term is committed, which can be extended by two years and then two further one-year periods, giving a potential end date of March 2031. The initial three-year term comes up in March 2027, NHS England says. The award notice lists a contract end date of 15 February 2027, 91 days from today, by our arithmetic.
Why the Contract Is Being Reopened
The FT ties the move to a backlash over Palantir’s role in the UK health service, with pressure from activists, Labour MPs and healthcare professionals. Andrea Egan, general secretary of the Unison union, called the platform “both technically and ethically bankrupt”, the FT reports.
A House of Commons Library briefing says two select committees have recommended the government does not extend the contract. It says NHS England’s chief data officer, Ayub Bhayat, told MPs in June 2026 that they would have to inform the supplier by December 2026 if they were not extending the contract.
The same briefing says the Health Innovation Minister told a committee in August 2026 that normal procurement timelines made it unlikely a successor contract could be in place by March 2027. Zubir Ahmed, a health minister at the Department of Health and Social Care, spoke in a Westminster Hall debate on 16 April 2026. NHS England quotes him as saying: “Of course, who contracts with the FDP will be open to question as we go forward and think about future contractual arrangements.”

What It Means for Palantir’s Numbers
Palantir’s 10-Q for the third quarter does not break out UK revenue: it says no country other than the United States represented 10% or more of total revenue. The words NHS and National Health Service do not appear in the filing’s text, by our search of it.
Rest-of-world revenue was $376.2 million in the quarter, 16% of the total, against $298.5 million and 25% a year earlier, the filing shows. That is growth of 26%, against 119% for the United States and 96% overall, by our arithmetic, as covered in our Palantir filing piece.
The Structural Read
As we read the FT and the Commons Library briefing together, timing is the constraint: NHS England has said it would have to tell the supplier by December 2026 if it were not extending, and a minister said a successor contract was unlikely to be in place by March 2027.
As we read the FT, the contest is now about who counts as British: Palantir may argue its NHS staff are UK-based, while ministers draft a new definition of a UK supplier before the formal process starts.
NHS England, FDP contract explainer
“Vendor lock-in is avoided through contractual limitations, a seven-year contract term, robust exit planning, standards and technical guidelines to utilise agnostic services that can be migrated.”
Three Implications
FOR PALANTIR The 10-Q does not break out UK revenue; rest-of-world revenue was $376.2 million in the third quarter, 16% of the total, per the filing.
FOR UK BIDDERS The FT names the Drystone consortium, Quantexa and, as a potential bidder, Oracle Health; the new UK supplier definition is expected before the formal process starts, per the FT.
RELATED Our Palantir filing piece covers the 10-Q in full.
The Business Engineer Lens
This story maps onto the Business Engineer framework Enterprise AI: From Software to Substrate.
The framework says “enterprise vendors don’t sell software anymore—they sell irreversibility.”
As we read it, the NHS re-tender tests that claim from the buyer’s side: NHS England says the contract was written with exit planning and migratable services, and a minister told MPs that ending it would cause disruption. The framework does not discuss the NHS or Palantir.
What Is Not Established
The procurement process, its timing, its value and the new definition of a UK supplier are described in the FT’s reporting; we read no government announcement of them. Whether Palantir will bid again is not stated in the FT article.
A web and Google News search for Drystone Health AI Collaboration at about 05:15 UTC returned the FT article and a Companies House listing, and no release from the consortium. We did not contact NHS England, the Department of Health and Social Care, Palantir, Quantexa, Oracle Health or the consortium for this piece.
The Bottom Line
The FT reports that the government is expected to rule out triggering the break clause in Palantir’s Federated Data Platform contract but to open a new procurement, which the Drystone consortium has said it will bid for and Quantexa is understood to be preparing for. The contract’s notice value is £182.2 million against a £330m forecast, neither of them committed.
In defence, Palantir faces a similar challenge from Helsing’s Clarity bid for the Maven contract.
95,000+ executives read Business Engineer for the AI strategy frameworks cited by ChatGPT, Claude, and Perplexity.
A note on sourcing. The report itself is the Financial Times article of 16 November 2026 (05:00 UTC) by Josh Gabert-Doyon and Chris Smyth, which we read in full; the bidders, the expected break-clause decision and the new procurement process are the FT’s reporting and have not been announced by the government in anything we read. Contract dates, the £182,242,760 notice value and the £330m forecast are from the Contracts Finder award notice; the term structure is from NHS England’s contract explainer; the select-committee and ministerial evidence is from the House of Commons Library briefing CBP-12264; Palantir’s revenue by geography is from its 10-Q for the quarter to 30 September 2026.
Percentages, averages and day counts are our arithmetic. NHS England, DHSC, Palantir, Quantexa, Oracle Health and the Drystone consortium were not contacted for this piece.
Sources: Financial Times, 16 Nov 2026 · Contracts Finder, FDP award notice · NHS England, FDP contract explainer · House of Commons Library, CBP-12264 · Palantir 10-Q, Q3 2026









